Monday, March 31, 2014
Sector-specific concerns plus
an investor rotation out of growth stocks have sent biotech shares tumbling.
Buysiders think the slide is a healthy correction rather than a sign the dance
music has stopped.
The iShares Nasdaq Biotechnology
(IBB) exchange traded fund hit a 52-week high of 275.4 on Feb. 25. Over the
past month, however, the IBB is off 13%, the BioCentury 100 Index is off 14%,
the NASDAQ Biotechnology Index is down 11% and the NYSE Arca Biotechnology